SLC1A5 and pancreatic neoplasm: This study demonstrates that pancreatic cancer cell‐derived EVs promote the uptake of Asn released from pancreatic cancer cells through the upregulation of SLC1A5 in PSCs, facilitating PSCs activation and pancreatic cancer resistance to GEM.